Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 528 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer: An Multicenter Open-label Randomized Clinical Trial
Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients
Neoadjuvant Chemotherapy Followed by Surgery Versus Upfront Surgery for Clearly Resectable Pancreatic Head Cancer and Periampullary Cancer: A Randomized Controlled Trial
Who cites it
528 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy of UFT combined with radiotherapy in advanced pancreatic cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and Meta-analysis of Latest Randomized Controlled Trials.Annals of surgical oncology · 2025Pooled it
- Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis.BJS open · 2025Pooled it
- A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.Annals of surgical oncology · 2026Trial
- Ferumoxtran-10-enhanced MRI for pre-operative metastatic lymph node detection in pancreatic, duodenal, or periampullary adenocarcinoma.European radiology · 2024Trial
- Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).Annals of surgical oncology · 2024Trial
- Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.Annals of surgical oncology · 2024Trial
- 11.5-Fr Large-Bore Plastic Stents Versus Fully Covered Self-Expandable Metallic Stents for the Management of Preoperative Endoscopic Biliary Obstruction in Pancreatic Cancer: A Multicenter Retrospective Cohort Study.Digestive diseases and sciences · 2026Article
- Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.Advances in radiation oncology · 2026Article
- Standardizing computed tomographic assessment of the mesopancreas in pancreatic cancer patients.Abdominal radiology (New York) · 2026Article
- Interpretable prediction of occult lymph node metastasis in pancreatic ductal adenocarcinoma using a model fusing habitat radiomics and deep learning.Abdominal radiology (New York) · 2026Article
- High SMAD4 Expression is Associated with Improved Clinical Outcomes in Patients with Resectable Pancreatic Cancer: An Analysis of NRG Oncology/RTOG 9704.International journal of radiation oncology, biology, physics · 2026Article
- TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer.Annals of surgical oncology · 2026Article
- Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis.Langenbeck's archives of surgery · 2026Observational
- Article
- Comparison of neoadjuvant therapy versus upfront surgery in resectable pancreatic adenocarcinoma: a retrospective study.Annals of medicine and surgery (2012) · 2026Article
- Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC survey.ESMO gastrointestinal oncology · 2026Article
- Pre-operative neutrophil-to-lymphocyte ratio significantly predicts local recurrence in pancreatic ductal adenocarcinoma.Annals of hepato-biliary-pancreatic surgery · 2026Article
- Review
468 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
31 authors.
Funding
Abstract
purposePreoperative chemoradiotherapy may improve the radical resection rate for resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven. PATIENTS AND
methodsIn this randomized phase III trial in 16 centers, patients with resectable or borderline resectable pancreatic cancer were randomly assigned to receive preoperative chemoradiotherapy, which consisted of 3 courses of gemcitabine, the second combined with 15 × 2.4 Gy radiotherapy, followed by surgery and 4 courses of adjuvant gemcitabine or to immediate surgery and 6 courses of adjuvant gemcitabine. The primary end point was overall survival by intention to treat.
resultsBetween April 2013 and July 2017, 246 eligible patients were randomly assigned; 119 were assigned to preoperative chemoradiotherapy and 127 to immediate surgery. Median overall survival by intention to treat was 16.0 months with preoperative chemoradiotherapy and 14.3 months with immediate surgery (hazard ratio, 0.78; 95% CI, 0.58 to 1.05;
conclusionPreoperative chemoradiotherapy for resectable or borderline resectable pancreatic cancer did not show a significant overall survival benefit. Although the outcomes of the secondary end points and predefined subgroup analyses suggest an advantage of the neoadjuvant approach, additional evidence is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.